Investigational drug more than doubles survival time for glioblastoma patients – BioNews Central A unique investigational drug formulation more than doubled the median survival and progression-free survival times of glioblastoma patients without causing dose-limiting toxic effects. ...

A unique #InvestigationalDrug formulation more than doubled the median #survival and #ProgressionFreeSurvival times of #glioblastoma patients without causing dose-limiting toxic effects.
#BrainCancer